JP2018530617A - ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用 - Google Patents

ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用 Download PDF

Info

Publication number
JP2018530617A
JP2018530617A JP2018538935A JP2018538935A JP2018530617A JP 2018530617 A JP2018530617 A JP 2018530617A JP 2018538935 A JP2018538935 A JP 2018538935A JP 2018538935 A JP2018538935 A JP 2018538935A JP 2018530617 A JP2018530617 A JP 2018530617A
Authority
JP
Japan
Prior art keywords
compound
alkyl
compounds
independently selected
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018538935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530617A5 (enExample
Inventor
クリストフェ シャビエル ブリス レジナルド
クリストフェ シャビエル ブリス レジナルド
ジーン ジョエル ジニー ラファエル
ジーン ジョエル ジニー ラファエル
マリー ジョンクール アグネス
マリー ジョンクール アグネス
ジョージス ピエール‐オリビエ ドヨン ジュリアン
ジョージス ピエール‐オリビエ ドヨン ジュリアン
ギルバート ラベグエレ フレデリク
ギルバート ラベグエレ フレデリク
ルフランソワ ジーン‐ミシェル
ルフランソワ ジーン‐ミシェル
マンモリティ オスカル
マンモリティ オスカル
アントワーヌ シュミット ベノイト
アントワーヌ シュミット ベノイト
エミエル ヴァン デル プラス スティーブン
エミエル ヴァン デル プラス スティーブン
ジャンヌ マリー メネット クリステル
ジャンヌ マリー メネット クリステル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2018530617A publication Critical patent/JP2018530617A/ja
Publication of JP2018530617A5 publication Critical patent/JP2018530617A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018538935A 2015-10-19 2016-10-14 ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用 Ceased JP2018530617A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518456.7 2015-10-19
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PCT/EP2016/074662 WO2017067848A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Publications (2)

Publication Number Publication Date
JP2018530617A true JP2018530617A (ja) 2018-10-18
JP2018530617A5 JP2018530617A5 (enExample) 2019-11-21

Family

ID=55131239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018538935A Ceased JP2018530617A (ja) 2015-10-19 2016-10-14 ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用

Country Status (18)

Country Link
US (1) US10508111B2 (enExample)
EP (1) EP3365341B1 (enExample)
JP (1) JP2018530617A (enExample)
KR (1) KR20180064528A (enExample)
CN (1) CN108137584A (enExample)
AR (1) AR106384A1 (enExample)
AU (1) AU2016343225A1 (enExample)
BR (1) BR112018007392A2 (enExample)
CA (1) CA3002255A1 (enExample)
CO (1) CO2018004765A2 (enExample)
GB (1) GB201518456D0 (enExample)
IL (1) IL258707A (enExample)
MX (1) MX2018004517A (enExample)
PH (1) PH12018500827A1 (enExample)
RU (1) RU2018117499A (enExample)
SG (1) SG11201803095UA (enExample)
TW (1) TW201718582A (enExample)
WO (1) WO2017067848A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
GB201702603D0 (en) * 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505077A (ja) * 2003-09-12 2007-03-08 ビーエーエスエフ　アクチェンゲゼルシャフト 動物害虫を駆除するために用いる６−ハロゲノ−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン類
JP2014508145A (ja) * 2011-02-09 2014-04-03 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤としての複素環化合物
WO2015103453A1 (en) * 2014-01-03 2015-07-09 Bristol-Myers Squibb Company Heteroaryl substituted nicotinamide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2432834A (en) * 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
RU2016110852A (ru) * 2013-09-27 2017-10-30 Нимбус Айрис, Инк. Ингибиторы irak и их применения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505077A (ja) * 2003-09-12 2007-03-08 ビーエーエスエフ　アクチェンゲゼルシャフト 動物害虫を駆除するために用いる６−ハロゲノ−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン類
JP2014508145A (ja) * 2011-02-09 2014-04-03 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤としての複素環化合物
WO2015103453A1 (en) * 2014-01-03 2015-07-09 Bristol-Myers Squibb Company Heteroaryl substituted nicotinamide compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUCKLEY, G. M. ET AL.: "IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18(12), JPN6020038396, 2008, pages 3656 - 3660, ISSN: 0004362965 *
TUMEY, L. N. ET AL.: "Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24(9), JPN6020038394, 2014, pages 2066 - 2072, ISSN: 0004362964 *

Also Published As

Publication number Publication date
GB201518456D0 (en) 2015-12-02
US20180305351A1 (en) 2018-10-25
PH12018500827A1 (en) 2018-10-29
CO2018004765A2 (es) 2018-07-19
WO2017067848A1 (en) 2017-04-27
KR20180064528A (ko) 2018-06-14
IL258707A (en) 2018-06-28
TW201718582A (zh) 2017-06-01
CN108137584A (zh) 2018-06-08
US10508111B2 (en) 2019-12-17
BR112018007392A2 (pt) 2018-10-16
RU2018117499A3 (enExample) 2020-01-24
AR106384A1 (es) 2018-01-10
EP3365341B1 (en) 2020-05-13
AU2016343225A1 (en) 2018-05-10
CA3002255A1 (en) 2017-04-27
RU2018117499A (ru) 2019-11-21
SG11201803095UA (en) 2018-05-30
MX2018004517A (es) 2018-06-27
EP3365341A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
CN113924146B (zh) 用于治疗疾病的新化合物及其药物组合物
CN112292129B (zh) 用于治疗疾病的新化合物及其药物组合物
JP7621277B2 (ja) 疾患の治療のための新規化合物及びその医薬組成物
EP3947378B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2018530617A (ja) ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用
JP2022526553A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP2020507612A (ja) Ｉｒａｋ阻害剤及びｊａｋ阻害剤を含む抗炎症組成物
CA3134735A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2025068090A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
KR20250130699A (ko) 알레르기 질환, 염증 질환, 대사 질환, 자가염증 질환, 자가면역 질환, 및 증식성 질환의 치료에 유용한 이미다조[4,5-b]피리딘 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200924

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201013

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210224